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Introduction {#sec0005}
============

Vulvovaginal candidiasis (VVC) is a primary opportunistic mycosis or secondary with endogenous or exogenous characteristics. It is also classified as a sexually transmitted disease (STD) and is caused by different species of *Candida.*[@bib0230], [@bib0235] The disease is characterized by inflammation of the genital mucosa as a response to the yeast proliferation.[@bib0240]

The genus *Candida* includes approximately 300 heterogeneous species with different morphological and functional features, and is currently found as a part of the normal flora in skin, digestive tract and mucous membrane, including the human genito-urinary tract.[@bib0245] Predominantly, VVC is caused by *C. albicans* and its prevalence can reach 85--95%.[@bib0230] However, infections caused by other species such as *C. tropicalis*, *C. glabrata*, *C. krusei*, *C. parapsilosis*, *C. kefyr* and *C. lusitaniae* have been reported as well.[@bib0230], [@bib0245], [@bib0250] According to literature these species are part of the vaginal mucous microbiota and they are present in 20--80% of healthy adult population, with clinical manifestations in 10% of pre-menopausal patients, 5--10% in menopausal and 30% of pregnant women.[@bib0255], [@bib0260]

Vulvovaginal infection, caused by *Candida* spp., affects women of reproductive age representing approximately 15--25% of the vaginitis cases.[@bib0265] These microorganisms usually remain hosted in the vaginal mucous only as colonizers; however, under inappropriate conditions the yeast reproduction increases inducing expression of virulence factors, which subsequently affects the mucous membrane, characteristic of the symptomatic VVC.[@bib0270]

Identification of strains that are isolated from VVC is crucial to clarify the distribution of *C. albicans* in relation to other species of *Candida* genus in different populations with manifestations of the infection. In clinical practice, the yeast identification is based on morphological and biochemical markers, including the automated methods.[@bib0275], [@bib0280] However, not all the species are precisely identified by such procedures. Therefore, molecular markers based on the sequencing of variable domain (D1/D2) from the 26S region and internal transcribed spacers (ITS) of the RNA gene were utilized in the present study to enable identification and detection of various strains.[@bib0285]

VVC is not a notified disease and generally the drug treatment is recommended based on the clinical diagnosis. Epidemiological molecular studies are relevant in context of establishment of species prevalence, elucidation of virulence factors and mechanisms of drug resistance so as to support the treatment protocols.[@bib0290]

A few studies have focused on the correlation of antifungal susceptibility with clinical results in VVC.[@bib0295] In spite of a considerable enhancement in the resistance profile among the various *Candida* species, fluconazole is still widely used for treatment of VVC.[@bib0230] Since it has been noticed that *C. albicans* displays a variable sensitivity to azoles derivatives, it seems crucial to identify its sensitivity profile against various drugs for a better therapeutic conduct.[@bib0300]

In view of such grounds, the current work aimed to evaluate *in vitro* susceptibility and molecular characterization of yeast from genus *Candida* that were isolated from the patients with infection and the patients with no clinical symptoms, for elucidation of epidemiological aspects of vulvovaginal candidiasis.

Materials and methods {#sec0010}
=====================

Test organism {#sec0015}
-------------

The present study analyzed vaginal material isolates from the patients assisted by an outpatient clinic of Toco-gynecology at the Clinical Hospital/UFPR, Paraná ([Table 1](#tbl0005){ref-type="table"}). The study was conducted from November 2011 to October 2012. The research work was approved by the Ethical Committee of Federal University of Paraná Clinical. Samples from 133 women were collected with their consent.

Casuistry {#sec0020}
---------

The study enrolled women, who were aged between 18 and 56 years, with or without VVC clinical symptoms, and who had not been administered any drug treatment in the last six months before collection of the samples. The patients were divided into two groups: colonized patients (without clinical symptoms) and infected patients.[@bib0230] The infected patients presented three or more of the following clinical symptoms: typical discharge, vaginal itching, vulvovaginal burning, dysuria and dyspareunia. Infected patient group was sub-divided into two sub-groups: (i) complicated -- which included women with a history of recurrence infection; and (ii) uncomplicated -- patients with sporadic episodes of the infection. The exclusion criteria were age (under 18 and over 56), pregnancy and women with immunosuppressive diseases and under treatment.

Collection, isolation and phenotypic identification {#sec0025}
---------------------------------------------------

The samples were collected by swabs, and each sample was sowed on Sabouraud Dextrose Agar medium followed by incubation at ±30 °C for a period of 48--120 h as per the growth parameters of each isolate. A presumptive identification of isolates was done by CHROMagar at 37 °C for 48 h.[@bib0305] Some of the isolates were identified by the API 20 AUX system (BioMérieux, France).

Molecular characterization of *Candida* isolates {#sec0030}
------------------------------------------------

DNA from the isolates was extracted by physical maceration of the samples in a mixture of silica/celite (2:1) in CTAB (cetyltrimethylammonium bromide). The isolated DNA was precipitated by CIA (acidic solution of chloroform-isoamyl alcohol) followed by sequencing on ABI3500 sequencer.[@bib0310] For ITS sequencing, the following primers were used: ITS1 (5′-TCCGTAGGTGAACCTGCGG-3′) and ITS4 (5′-TCCTCCGCTTATTGATATGC-3′) and the reaction conditions of sequencing were as follows[@bib0315]: one cycle at 94 °C for 2 min, followed by 30 cycles at (94 °C for 30 s, 56 °C for 1 min, 72 °C for 1 min) and a final extension at 72 °C for 3 min.[@bib0310] For amplification of D1/D2 region, the primers NL-1 (5′-GCATATCAATAAGCGGAGGAAAAG-3′) and NL-4 (5′-GGTCCGTGTTTCAAGACGG-3′) were used following the same reaction conditions, as listed above.[@bib0320]

For ABC genotyping of *C. albicans*, the primers CA-int-L (5′-ATAAGGGAAGTCGGCAAAATAGATCCGTAA-3′) and CA-int-R (5′-CCTTGGCTGTGGTTTCGCTAGATAGTAGAT-3′) were used.[@bib0325] The genotyping was based on the presence or absence of a DNA insert, which codes for the ribosomal 26S RNA, dividing *C. albicans* in four groups[@bib0325]: A (*C. albicans* -- 450 bp), B (*C. albicans* -- 840 bp), C (*C. stellatoidea* -- 840 bp) and D (*C. dubliniensis* -- 1080 bp).

Alignment and phylogenetic construction {#sec0035}
---------------------------------------

The obtained sequences were edited using the Staden program version 1.6, and were compared by the BLAST program for detection of the similarities using reference sequences available in the data bank (NCBI, National Center for Biotechnology Information -- <http://www.ncbi.nlm.nih.gov/>).[@bib0330], [@bib0335] The Mafft program (<http://mafft.cbrc.jp/alignment/server/>) was used for the alignment; and visual inspection was done by MEGA 5.1 version.[@bib0340] Forty sequences of *Candida* isolates were submitted for phylogenetic analysis using *Schizosaccharomyces pombe* strain U40085 as outgroup.[@bib0325] The Maximum Likelihood phylogenetic tree was built with 100 bootstraps, based on the evolutionary model Tamura-3 parameters with using 5.1 version of the MEGA software for final editing.[@bib0340]

*In vitro* susceptibility tests {#sec0040}
-------------------------------

The *in vitro* susceptibility tests were done by micro-dilution method of broth, as per the Norm M27-A3 recommendations provided by the Clinical and Laboratory Standards Institute.[@bib0345] The antifungals used were amphotericin B (Sigma--Aldrich 110 Química, Madrid, Spain), ketoconazole (Pharma Nostra, Brazil), itraconazole (Fragon), fluconazole (Pfizer, Madrid, Spain) and nystatin (Pharma Nostra, Brazil). The samples were diluted in RPMI (Roswell Park Memorial Institute Medium)-1640 medium (Sigma) and incubated at 37 °C for 48 h. According to the CLSI criteria, the sensitivity profile is classified as sensitive, dose-dependent sensitivity and resistant.

Results {#sec0045}
=======

A total of 40 isolates were obtained from 133 cervicovaginal samples, which were previously identified by CHROMagar and API 20AUX systems. On the basis of ITS and D1/D2 sequences, the isolates could be attributed to the genera *Candida* and *Saccharomyces* ([Table 1](#tbl0005){ref-type="table"}). Among the isolates studied, 20 belonged to the colonized group, 11 were from the complicated infection group and 9 were from the uncomplicated infection group.

A tree was constructed using maximum likelihood analysis and the evolutionary model Kimura 2-parameter with 100 *bootstraps.* A total of 1959 sites were evaluated, of which, 786 were conserved sites, 1092 were variable sites, 712 sites provided parsimonious information (pi), and 361 were unique sites. The empirical basis frequencies were pi (A): 0.225836 pi (C): 0.283009 pi (G): 0.238533, pi (t) 0.252622. The phylogenetic tree was generated by using 18 strains as references, which included various types of strains of *Candida* species, *Kluyveromyces marxianus*, *K. lactis*, *Saccharomyces cerevisiae*, *Torulaspora delbrueckii*, keeping *Schizosaccharomyces pombe* as an outgroup.

The evaluated VVC isolates were identified to be *C. albicans*, *C. dubliniensis*, *C. guilliermondii*, *C. kefyr*, *Saccharomyces cerevisiae* and *C. glabrata* and were found to be distributed into six clades supported by bootstrap values ([Fig. 1](#fig0005){ref-type="fig"}). The phylogenetic data corroborated with the biochemical data, except for the HC03IC isolate that was identified as *C. albicans* by the API 20AUX system, but as *C. dubliniensis* by the phylogenetic analysis ([Fig. 1](#fig0005){ref-type="fig"}).

According to the tree, most of the analyzed clinical isolates were identified to be *C. albicans*, with 33 isolates clustered in Albicans clade (bs, 100%). Analysis revealed that *C. albicans* isolates could not be separated according to the studied groups, *i.e.*, colonized, complicated, and uncomplicated infection groups. In Guilliermondii clade (bs, 99%), the clinical isolate (HC08C) and *P. guilliermondii* (NRRL Y-2075) type strain were grouped. The isolate (HC02C) from the colonized group and *Saccharomyces cerevisiae* type were clustered in Saccharomyces clade (bs, 100%). Kefyr clade consisted of *Kluyveromyces marxianus* (NRRL Y-8281), *Candida kefyr* teleomorph strain CBS 712, *K. marxianus var*. *Kluyveromyces lactis* strain NRRL Y-8279 and HC09C isolate of C. *kefyr*. Three isolates were classified into the Glabrata clade (HC01C, HC07C and HC10C), belonging to the colonized group and *C. glabrata* type (5478) with 100% bootstrap.

Based on the molecular data, amidst the 40 isolates that were obtained from vaginal samples, the most prevalent species was *C. albicans* (82.5%), followed by *C. glabrata* (7.5%), *C. guilliermondii* (2.5%), *C. kefyr* (2.5%), *C. dubliniensis* (2.5%) and *Saccharomyces cerevisiae* (2.5%). Among the colonized group alone, a total of 20 isolates belonging to five different species *C. albicans* (60%), *C. glabrata* (25%), *C. guilliermondii* (5%), *C. kefyr* (5%) and *Saccharomyces cerevisiae* (5%) were identified. A total of 9 isolates obtained from the uncomplicated infection group were *C. albicans* (100%). In the complicated infection group, 11 isolates were from two different *Candida* species: *C. dubliniensis* (9.1%) and *C albicans* (90.9%).

Regarding the ABC genotyping of *C. albicans*, at least two different genotypes (A and B) were observed, although 25 isolates belonged to type A and 7 isolates to type B, it was not possible to establish a correlation amidst the genotypes identified and the susceptibility profile of the tested drugs ([Fig. 2](#fig0010){ref-type="fig"}).

The susceptibility testing results of the studied isolates from different patient groups are summarized in [Table 2](#tbl0010){ref-type="table"}. In the colonized group (I), all isolates of *C. albicans* (*n* = 14) showed a dose-dependent sensitivity (SDD) to nystatin (8.0 μg/mL) and sensitivity (S) to itraconazole (0.0625 μg/mL), fluconazole (0.125 μg/mL), amphotericin B (0.03--1.0 μg/mL) and ketoconazole (0.0625 μg/mL). Three *C. glabrata* isolates (HC01C, HC02C and HC07C) were resistant (R) to itraconazole (4.0 μg/mL), SDD for the fluconazole (4.0--16 μg/mL), nystatin (8.0 μg/mL) and sensitive to amphotericin B (0.03--1.0 μg/mL) and ketoconazole (1.0--4.0 μg/mL). The isolate of *C. guilliermondii* (HC16C) showed SDD to nystatin (8.0 μg/mL), resistance to amphotericin B (2.0 μg/mL), sensitivity to itraconazole (0.0625 μg/mL), fluconazole (0.125 μg/mL), and ketoconazole (0.0625 μg/mL). *C. kefyr* (HC09C) presented SDD to itraconazole (0.25), nystatin (4.0 μg/mL), and sensitivity for fluconazole (0.25 μg/mL), amphotericin B (1.0 μg/mL) and ketoconazole (0.0625 μg/mL). Furthermore, *S. cerevisiae* isolate (HC02C) was SDD to nystatin (8.0 μg/mL) and sensitive to itraconazole (0.0625 μg/mL), fluconazole (0.125 μg/mL), amphotericin B (0.03--1.0 μg/mL) and ketoconazole (0.0625 μg/mL).

In the complicated infection group (II), one strain of *C. albicans* isolate (HC01IC) was found to be SDD to itraconazole (0.0625--0.25 μg/mL); all isolates (*n* = 10) were resistant to nystatin (≥64 μg/mL) and sensitive to fluconazole (0.125--2.0 μg/mL), amphotericin B (1.0 μg/mL) and ketoconazole (0.0625 μg/mL). *C. dubliniensis* isolate (HC03IC) was resistant to nystatin (≥64 μg/mL) and presented sensitivity toward the itraconazole (0.0625 μg/mL), fluconazole (0.125--2.0 μg/mL), amphotericin B (0.5--1.0 μg/mL) and ketoconazole (0.0625 μg/mL). Finally, in the uncomplicated infections group (III), all the isolates (*n* = 9) of *C. albicans* were SDD to nystatin (8.0 μg/mL) and sensitive toward itraconazole (0.0625 μg/ml), fluconazole (0.125--2.0 μg/mL), amphotericin B (0.5--1.0 μg/mL) and ketoconazole (0.0625 μg/mL).

Discussion {#sec0050}
==========

Identification of *Candida* species that causes VVC is highly desirable in microbiological practice, as it may help in clarifying the prevalence and incidence of species that affects the susceptible population. Moreover, determination of susceptibility of *Candida* to the antifungal drugs may be crucial in context of the recurrent clinical forms of VVC. Several studies have demonstrated the occurrence of vulvovaginitis due to *Candida* species, indicating heterogeneity among isolates from different geographical regions. In the present study, the prevalent species were[@bib0240], [@bib0350], [@bib0355], [@bib0360] *C. albicans*, followed by *C. glabrata*, *C. guilliermondii*, *C. kefyr*, *C. dubliniensis* and *Saccharomyces cerevisiae*, thereby suggesting an increase of infection by non-albicans *Candida*. An increase in infections that are caused by non-albicans *Candida* has been registered, although *C. albicans* is still the most isolated species in VVC clinical cases.[@bib0290], [@bib0365], [@bib0370], [@bib0375], [@bib0380] Furthermore, the cultural and ethnic differences may also influence the isolation rate of yeast from vulvovaginitis samples.[@bib0385], [@bib0390] The lack of data on epidemiology and genetic variability reinforces the importance of epidemiological studies by molecular methods.[@bib0255], [@bib0360], [@bib0395], [@bib0400], [@bib0405]

The colonized group investigated in the current study presented a wide diversity of species such as *C. albicans*, *C. glabrata*, *C. guilliermondii*, *C. kefyr* and *Saccharomyces cerevisiae*. In addition, *C. albicans* was found to be prevalent (*n* = 19) in the infection group and *C. dubliniensis* (*n* = 1) isolates were observed only in the complicated infection group ([Table 2](#tbl0010){ref-type="table"}). The microbiota species found in colonized women are the same as reported in VVC.[@bib0230], [@bib0245], [@bib0360], [@bib0375], [@bib0400] Vaginitis caused by *S. cerevisiae* is rare and it has been isolated from an asymptomatic patient.[@bib0410], [@bib0415] This corroborates with the findings of the present study.

The VVC *Candida albicans* isolates, analyzed by us, were clustered into a single clade, indicating a monophyletic group ([Fig. 1](#fig0005){ref-type="fig"}), which is in concordance with the data already reported by several authors.[@bib0380], [@bib0420] The strain, identified as *C. albicans* (HC03IC) by biochemical test, proved to be *C. dubliniensis* according to the phylogenetic analysis. A lack of correlation between the phenotypic and molecular identification of the samples can be justified by the limitations of the commercial identification system, which do not allow distinguishing the yeast species, which have minor phenotypic differences.[@bib0425], [@bib0430] Therefore, multilocus analyses are needed in order to identify *Candida* species.[@bib0380] In the ABC genotyping, two different genotypes among *C. albicans* isolates were detected. The genotype A was observed in 75.7% of the isolates, and the isolates of genotype B were present in all the analyzed groups. However, it had a higher occurrence in the uncomplicated infected group ([Fig. 2](#fig0010){ref-type="fig"}). It has been reported that the candidiasis that is caused by *C. albicans* of genotype B has a higher tendency for persistent infections, though further studies with larger populations for a better assessment are required.[@bib0405]

In the current analysis, all the *C. albicans* isolates from the complicated group, regardless of genotype, were resistant to nystatin and susceptible to other tested antifungals, except for the isolate HC04IC that showed SDD to fluconazole. In the uncomplicated infections group, the isolates of *C. albicans* were SDD to nystatin and susceptible to other tested antifungals. The same was observed in the isolates from the group of colonized patients. Concerning the non-albicans *Candida* species, the isolate of *C. dubliniensis* was resistant only to nystatin, the *C. glabrata* isolates were resistant to itraconazole and SDD to fluconazole and nystatin. These results contrast from the previous reports that regarded *C. glabrata* isolates as resistant and SDD to fluconazole.[@bib0435] Besides, *C. kefyr* strain presented SDD to itraconazole and nystatin, and a similar susceptibility profile was previously reported.[@bib0275] In other studies, similar results were obtained, reporting that VVC species strains of genus *Candida* presented resistance and also a high frequency of SDD for nystatin and sensitivity to others tested drugs.[@bib0355], [@bib0400], [@bib0440]

The isolate of *C. guilliermondii* showed SDD to nystatin and resistance to amphotericin B. According to the literature, the treatment is problematical due to a low sensitivity for some antifungal classes, especially for fluconazole, itraconazole and amphotericin B; and VVC infections caused by *C. guilliermondii* are rare.[@bib0235] Furthermore, we obtained an isolate of *S. cerevisiae* SDD to nystatin, which differed from the data previously reported for this species, which demonstrated that *S. cerevisiae* isolates were resistant to fluconazole, posaconazole, and itraconazole.[@bib0445]

There are several factors that can influence the clinical response to treatment of VVC, as evident from different reports showing variation in the *in vitro* susceptibility and *in vivo* response to the drug.[@bib0420], [@bib0450] Through *in vitro* susceptibility testing, it was observed that all the isolates were sensitive to ketoconazole, although fluconazole remains the drug of choice for VVC treatment. Such results indicate that the susceptibility profile for the isolates may not be a factor related to the recurrence of the disease. Therefore, it may be concluded that the molecular analysis provides accurate identification of *Candida* species isolated from patients with VVC. Hence, our findings demonstrated the importance of molecular tools for identification of the isolates and also to elucidate the epidemiology of VVC.
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![The phylogenetic tree of maximum likelihood based on the alignment of the entire region of its1/its2 and D1/D2 was built using 100 bootstrap, using the evolutionary model Tamura-3 parameters with program Mega version 5.1. *Schizosaccharomyces pombe* was used as an outgroup. The tree showed 6 clades (Albicans; Dubliniensis; Guilliermondii, Saccharomyces; Kefyr; Glabrata) diversified according to the isolated species. For a thorough understanding, the evaluated groups in this study are represented by colored squares for discernment: the brown square refers to the colonized group; one red square indicates isolates from the uncomplicated infection group; the two red squares represent the group with complicated infection.](gr1){#fig0005}

![Agarose electrophoresis ABC genotyping of the *C. albicans* from the different studied groups, genotype A (*C. albicans* -- 450 bp) and B (*C. albicans* -- 840 bp). The lanes 2--14 correspond to the colonized group; 15--23 to the uncomplicated infection group and 24--33 to the complicated infection group. Lane 34 represents a blank; the lanes 1 and 35 indicate standard 1 kb molecular weight markers (Invitrogen, Carlsbad, Ca, USA).](gr2){#fig0010}

###### 

List of reference strains and the clinical isolates.

  Name                          Number of reference   Substrate                 Geographical indication   GenBank access                           
  ----------------------------- --------------------- ------------------------- ------------------------- ---------------------------------------- ----------------------------------------
  *Candida albicans*            CBS 562               Clinical isolate          Australia                 [EF567995](ncbi-n:EF567995){#intr0005}   [U45776](ncbi-n:U45776){#intr0010}
  *Candida dubliniensis*        CBS 7987              Clinical isolate          Japan                     [AB035589](ncbi-n:AB035589){#intr0015}   [U57685](ncbi-n:U57685){#intr0020}
  *Candida inconspícua*         CBS 180               Clinical isolate          Australia                 [AJ853766](ncbi-n:AJ853766){#intr0025}   [U71062](ncbi-n:U71062){#intr0030}
  *Candida intermedia*          CBS 572               Clinical isolate          Australia                 [EF568011](ncbi-n:EF568011){#intr0035}   [U44809](ncbi-n:U44809){#intr0040}
  *Candida glabrata*            CBS 138               --                        Ireland                   [AY198398](ncbi-n:AY198398){#intr0045}   [U44808](ncbi-n:U44808){#intr0050}
  *Candida haemulonii*          CBS 5149              --                        Spain                     [JX459660](ncbi-n:JX459660){#intr0055}   [U44812](ncbi-n:U44812){#intr0060}
  *Candida tropicalis*          CBS 94                Clinical isolate          Japan                     [AB437068](ncbi-n:AB437068){#intr0065}   [U45749](ncbi-n:U45749){#intr0070}
  *Clavispora lusitaniae*       CBS 6986              Urine                     Bulgaria                  [EF568049](ncbi-n:EF568049){#intr0075}   [U44817](ncbi-n:U44817){#intr0080}
  *Debaryomyces carsonii*       CBS 2285              Clinical isolate          USA                       [AJ853767](ncbi-n:AJ853767){#intr0085}   [U45743](ncbi-n:U45743){#intr0090}
  *Kluyveromyces marxianus*     CBS 712               Clinical isolate          Australia                 [EF568057](ncbi-n:EF568057){#intr0095}   [U94924](ncbi-n:U94924){#intr0100}
  *Kluyveromyces lactis*        CECT1961              Environmental             USA                       [AJ401704](ncbi-n:AJ401704){#intr0105}   [U94922](ncbi-n:U94922){#intr0110}
  *Meyerozyma guilliermondii*   CBS 2030              Clinical isolate          Australia                 [EF568003](ncbi-n:EF568003){#intr0115}   [U45709](ncbi-n:U45709){#intr0120}
  *Pichia fermentans*           L1B                   Environmental isolates    UK                        [FJ713081](ncbi-n:FJ713081){#intr0125}   [U75726](ncbi-n:U75726){#intr0130}
  *Pichia membranifaciens*      23                    --                        Spain                     [JQ410476](ncbi-n:JQ410476){#intr0135}   [AJ508586](ncbi-n:AJ508586){#intr0140}
  *Pichia segobiensis*          CECT 10-210           --                        Spain                     [DQ409166](ncbi-n:DQ409166){#intr0145}   [U45742](ncbi-n:U45742){#intr0150}
  *Torulaspora delbrueckii*     CBS 1146              Clinical isolate          Australia                 [EF568083](ncbi-n:EF568083){#intr0155}   [AJ508558](ncbi-n:AJ508558){#intr0160}
  *Saccharomyces cerevisiae*    NRRL Y-12632          --                        USA                       [AM900404](ncbi-n:AM900404){#intr0165}   [AY048154](ncbi-n:AY048154){#intr0170}
  *Schizosaccharomyces pombe*   NRRL Y-12796          --                        USA                       [AY251633](ncbi-n:AY251633){#intr0175}   [U40085](ncbi-n:U40085){#intr0180}
  *Candida glabrata*            HC01                  Cervicovaginal contents   Brazil                    [KJ651873](ncbi-n:KJ651873){#intr0185}   [KJ624025](ncbi-n:KJ624025){#intr0190}
  *Saccharomyces cerevisiae*    HC02                  Cervicovaginal contents   Brazil                    --                                       [KJ624026](ncbi-n:KJ624026){#intr0195}
  *Candida albicans*            HC03                  Cervicovaginal contents   Brazil                    [KJ651903](ncbi-n:KJ651903){#intr0200}   [KJ624027](ncbi-n:KJ624027){#intr0205}
  *Candida albicans*            HC04                  Cervicovaginal contents   Brazil                    [KJ651904](ncbi-n:KJ651904){#intr0210}   [KJ624028](ncbi-n:KJ624028){#intr0215}
  *Candida albicans*            HC05                  Cervicovaginal contents   Brazil                    [KJ651905](ncbi-n:KJ651905){#intr0220}   [KJ624029](ncbi-n:KJ624029){#intr0225}
  *Candida albicans*            HC06                  Cervicovaginal contents   Brazil                    [KJ651906](ncbi-n:KJ651906){#intr0230}   [KJ624030](ncbi-n:KJ624030){#intr0235}
  *Candida glabrata*            HC07                  Cervicovaginal contents   Brazil                    [KJ651907](ncbi-n:KJ651907){#intr0240}   [KJ624031](ncbi-n:KJ624031){#intr0245}
  *Candida guilliermondii*      HC08                  Cervicovaginal contents   Brazil                    [KJ651908](ncbi-n:KJ651908){#intr0250}   [KJ624032](ncbi-n:KJ624032){#intr0255}
  *Candida kefyr*               HC09                  Cervicovaginal contents   Brazil                    [KJ651909](ncbi-n:KJ651909){#intr0260}   [KJ624033](ncbi-n:KJ624033){#intr0265}
  *Candida glabrata*            HC10                  Cervicovaginal contents   Brazil                    [KJ651910](ncbi-n:KJ651910){#intr0270}   [KJ624034](ncbi-n:KJ624034){#intr0275}
  *Candida albicans*            HC11                  Cervicovaginal contents   Brazil                    [KJ651874](ncbi-n:KJ651874){#intr0280}   [KJ624035](ncbi-n:KJ624035){#intr0285}
  *Candida albicans*            HC12                  Cervicovaginal contents   Brazil                    [KJ651875](ncbi-n:KJ651875){#intr0290}   [KJ624036](ncbi-n:KJ624036){#intr0295}
  *Candida albicans*            HC13                  Cervicovaginal contents   Brazil                    --                                       [KJ624037](ncbi-n:KJ624037){#intr0300}
  *Candida albicans*            HC14                  Cervicovaginal contents   Brazil                    [KJ651876](ncbi-n:KJ651876){#intr0305}   [KJ624038](ncbi-n:KJ624038){#intr0310}
  *Candida albicans*            HC15                  Cervicovaginal contents   Brazil                    [KJ651877](ncbi-n:KJ651877){#intr0315}   [KJ624039](ncbi-n:KJ624039){#intr0320}
  *Candida albicans*            HC16                  Cervicovaginal contents   Brazil                    [KJ651878](ncbi-n:KJ651878){#intr0325}   [KJ624040](ncbi-n:KJ624040){#intr0330}
  *Candida albicans*            HC17                  Cervicovaginal contents   Brazil                    [KJ651879](ncbi-n:KJ651879){#intr0335}   [KJ624041](ncbi-n:KJ624041){#intr0340}
  *Candida albicans*            HC18                  Cervicovaginal contents   Brazil                    [KJ651880](ncbi-n:KJ651880){#intr0345}   [KJ624042](ncbi-n:KJ624042){#intr0350}
  *Candida albicans*            HC19                  Cervicovaginal contents   Brazil                    [KJ651881](ncbi-n:KJ651881){#intr0355}   [KJ624043](ncbi-n:KJ624043){#intr0360}
  *Candida albicans*            HC20                  Cervicovaginal contents   Brazil                    [KJ651882](ncbi-n:KJ651882){#intr0365}   [KJ624044](ncbi-n:KJ624044){#intr0370}
  *Candida albicans*            HC01IC                Cervicovaginal contents   Brazil                    [KJ651883](ncbi-n:KJ651883){#intr0375}   [KJ624045](ncbi-n:KJ624045){#intr0380}
  *Candida albicans*            HC02IC                Cervicovaginal contents   Brazil                    [KJ651884](ncbi-n:KJ651884){#intr0385}   [KJ624046](ncbi-n:KJ624046){#intr0390}
  *Candida dubliniensis*        HC03IC                Cervicovaginal contents   Brazil                    [KJ651885](ncbi-n:KJ651885){#intr0395}   [KJ624047](ncbi-n:KJ624047){#intr0400}
  *Candida albicans*            HC04IC                Cervicovaginal contents   Brazil                    [KJ651886](ncbi-n:KJ651886){#intr0405}   [KJ624048](ncbi-n:KJ624048){#intr0410}
  *Candida albicans*            HC05IC                Cervicovaginal contents   Brazil                    [KJ651887](ncbi-n:KJ651887){#intr0415}   [KJ624049](ncbi-n:KJ624049){#intr0420}
  *Candida albicans*            HC06IC                Cervicovaginal contents   Brazil                    [KJ651888](ncbi-n:KJ651888){#intr0425}   [KJ624050](ncbi-n:KJ624050){#intr0430}
  *Candida albicans*            HC07IC                Cervicovaginal contents   Brazil                    [KJ651889](ncbi-n:KJ651889){#intr0435}   [KJ624051](ncbi-n:KJ624051){#intr0440}
  *Candida albicans*            HC08IC                Cervicovaginal contents   Brazil                    [KJ651890](ncbi-n:KJ651890){#intr0445}   [KJ624052](ncbi-n:KJ624052){#intr0450}
  *Candida albicans*            HC09IC                Cervicovaginal contents   Brazil                    [KJ651891](ncbi-n:KJ651891){#intr0455}   [KJ624053](ncbi-n:KJ624053){#intr0460}
  *Candida albicans*            HC10IC                Cervicovaginal contents   Brazil                    [KJ651892](ncbi-n:KJ651892){#intr0465}   [KJ624054](ncbi-n:KJ624054){#intr0470}
  *Candida albicans*            HC11IC                Cervicovaginal contents   Brazil                    [KJ651893](ncbi-n:KJ651893){#intr0475}   [KJ624055](ncbi-n:KJ624055){#intr0480}
  *Candida albicans*            HC01INC               Cervicovaginal contents   Brazil                    [KJ651894](ncbi-n:KJ651894){#intr0485}   [KJ624056](ncbi-n:KJ624056){#intr0490}
  *Candida albicans*            HC02INC               Cervicovaginal contents   Brazil                    [KJ651895](ncbi-n:KJ651895){#intr0495}   [KJ624057](ncbi-n:KJ624057){#intr0500}
  *Candida albicans*            HC03INC               Cervicovaginal contents   Brazil                    [KJ651896](ncbi-n:KJ651896){#intr0505}   [KJ624058](ncbi-n:KJ624058){#intr0510}
  *Candida albicans*            HC04INC               Cervicovaginal contents   Brazil                    [KJ651897](ncbi-n:KJ651897){#intr0515}   [KJ624059](ncbi-n:KJ624059){#intr0520}
  *Candida albicans*            HC05INC               Cervicovaginal contents   Brazil                    [KJ651898](ncbi-n:KJ651898){#intr0525}   [KJ624060](ncbi-n:KJ624060){#intr0530}
  *Candida albicans*            HC06INC               Cervicovaginal contents   Brazil                    [KJ651899](ncbi-n:KJ651899){#intr0535}   [KJ624061](ncbi-n:KJ624061){#intr0540}
  *Candida albicans*            HC07INC               Cervicovaginal contents   Brazil                    [KJ651900](ncbi-n:KJ651900){#intr0545}   [KJ624062](ncbi-n:KJ624062){#intr0550}
  *Candida albicans*            HC08INC               Cervicovaginal contents   Brazil                    [KJ651901](ncbi-n:KJ651901){#intr0555}   [KJ624063](ncbi-n:KJ624063){#intr0560}
  *Candida albicans*            HC09INC               Cervicovaginal contents   Brazil                    [KJ651902](ncbi-n:KJ651902){#intr0565}   [KJ624064](ncbi-n:KJ624064){#intr0570}

(--) data not provided; HC: clinical hospital/UFPR; C: colonized; IC: complicated infection; INC: non-complicated infection.

###### 

Variations in the minimum inhibitory concentration (MIC) of antifungals for the different study groups.

  Isolate species          Total of samples   Itraconazole             Fluconazole           Nystatin             Amphotericin B      Ketoconazole
  ------------------------ ------------------ ------------------------ --------------------- -------------------- ------------------- ----------------
  *C. albicans* (I)        14                 0.0625--0.0625           0.125--0.125          8.0--8.0 (SDD=14)    0.03--1.0           0.0625--0.0625
  C. *albicans* (II)       10                 0.0625--0.25 (SDD = 1)   0.125--2.0            ≥64 (R = 10)         0.5--1.0            0.0625--0.25
  *C. albicans* (III)      09                 0.125--0.125             0.125--0.125          8.0--8.0 (SDD = 9)   1.0--1.0            0.0625--0.0625
  *C. glabrata* (I)        03                 2.0--4.0 (R = 3)         4.0--16.0 (SDD = 1)   8.0--8.0 (SDD = 3)   0.03--1.0           1.0--4.0
  *C. guillermondii* (I)   01                 0.0625--0.0625           0.125--8.0            8.0 (SDD = 1)        0.25--2.0 (R = 1)   0.0625--2.5
  *C. Kefyr* (I)           01                 0.25 (SDD = 1)           0.25                  4.0 (SDD = 1)        1.0                 0.0625
  *S. cerevisiae* (I)      01                 0.0625--0.0625           0.125--0.125          8.0--8.0 (SDD = 1)   0.03--1.0           0.0625--0.0625
  *C. dubliniensis* (II)   01                 0.0625--0.0625           0.125--2.0            ≥ 64 (R = 1)         0.5--1.0            0.0625--0.25

SDD: sensitivity dose dependent; R: resistant; S: sensitivity; I: colonized group; II: complicated infection group; III: uncomplicated group.
